Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05300438
Recruitment Status : Recruiting
First Posted : March 29, 2022
Last Update Posted : April 25, 2022
Information provided by (Responsible Party):
Tyligand Bioscience (Shanghai) Limited

Brief Summary:
TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies.

Condition or disease Intervention/treatment Phase
Cancer (With or Without Metastasis) Drug: TSN084 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 74 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TSN084 Tablets in Patients With Advanced Malignant Tumors.
Actual Study Start Date : February 18, 2022
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2025

Arm Intervention/treatment
Experimental: TSN084 Drug: TSN084
TSN084 administered orally as a tablet.

Primary Outcome Measures :
  1. Number of patients with dose limiting toxicity [ Time Frame: Every subject's DLT observation window is 28 days. ]
    Number of patients with dose limiting toxicity.

  2. Incidence of Treatment-Emergent Adverse Events [ Time Frame: From first dose to 28 ±7 days after last dose ]
    Incidence of adverse events, Treatment Emergent Adverse Event (TEAE), Serious Adverse Event (SAE), their relationship with the investigational product and respective severity. Adverse events and laboratory test values will be graded according to NCI-CTCAE V5.0.

  3. Number of patients with c-Met, NTRK, FLT, Axl or CDK8/19 aberration. [ Time Frame: From first dose up to day 15 in the first 28-day cycle ]
    Detection of gene mutations, gene transcriptions, or protein expression in tumor tissue and blood ctDNA, including but not limited to c-Met, NTRK, FLT, Axl, CDK8/19, etc., and conduct correlation analysis with dose level, drug exposure, efficacy, and safety of TSN084 in patients with advanced maliginant tumors.

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) [ Time Frame: From first dose to day 1 in the second 28-day cycle ]
    To characterize the pharmacokinetic (PK) properties of TSN084 in patients with advanced malignant tumors.

  2. Time to Cmax (Tmax) [ Time Frame: From first dose to day 1 in the second 28-day cycle ]
    To characterize the pharmacokinetic (PK) properties of TSN084 in patients with advanced malignant tumors.

  3. Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC 0-t) [ Time Frame: From first dose to day 1 in the second 28-day cycle ]
    To characterize the pharmacokinetic (PK) properties of TSN084 in patients with advanced malignant tumors.

  4. Objective response rate (ORR) defined as the proportion of patients who have a CR or PR [ Time Frame: From first dose to within 3 days of last dose. ]
    Tumor response assessments by the corresponding criteria by RECIST v1.1 to assess Objective response rate (ORR)

  5. Duration of response (DoR) [ Time Frame: From first dose to within 3 days of last dose. ]
    Tumor response assessments by the corresponding criteria by RECIST v1.1 to assess Duration of response (DoR).

  6. Disease control rate (DCR) [ Time Frame: From first dose to within 3 days of last dose. ]
    Tumor response assessments by the corresponding criteria by RECIST v1.1 to assess Disease control rate (DCR) after the study treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women ≥18 years old.
  • The following three points are evaluated by the investigator and are deemed suitable to participate in the study: A. The subject fully understands the requirements of the study and voluntarily signs the written informed consent; B. Be able to comply with the medication requirements of the study and all study related procedures and evaluations; C. Not deemed as potentially unreliable and/or uncooperative.
  • Meeting the requirements of tumor types shown below: Phase Ia Study: Histological or cytological diagnosis of locally advanced, relapsed, or metastatic malignancies, not amenable to standard therapy or for which no standard therapy is available. Phase Ib study: Histological or cytological diagnosis of the locally advanced, relapsed, or metastatic malignancies not amenable to standard therapy or for which no standard therapy is available. The specific tumor types/basket design with specific driven gene(s) will be determined by the principal investigator and the sponsor based on the Phase Ia study result.
  • Survival expectations are ≥ 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 for Phase Ia, while 0 to 2 for Phase Ib. Subjects with advanced or metastatic malignancies who had at least one evaluable lesion during phase Ia study, while at least one measurable lesion during phase Ib study according to RECIST V1.1.
  • Patients with adequate organ function at the time of screening (requiring no blood transfusion, no use of hematopoietic stimulating factor or human albumin within 14 days prior to screening), specifically defined as:

    1. Blood routine: Absolute neutrophil count (ANC) ≥ 1.5×109/L; Platelet count (PLT) ≥100×109/L; Hemoglobin (HGB) ≥ 90 g/L;
    2. Liver function: Serum Total bilirubin (TBIL) ≤ 1.5 Upper limit of normal value (ULN), and serum TBIL≤ 3×ULN in patients with liver metastasis or confirmed Gilbert syndrome. Alanine aminotransferase (ALT) and Aspartate transferase (AST) ≤ 2.5×ULN in subjects without liver metastasis; ALT or AST≤ 5×ULN in subjects with liver metastasis;
    3. Renal function: estimated creatinine clearance (CLcr) ≥ 60 mL/min as calculated using Cockcroft-Gault formula (Cockcroft DW 1976);
    4. Coagulation function: Activated Partial thromboplastin Time (APTT) and international normalized ratio (INR) ≤ 1.5×ULN (or within target range if on anticoagulation therapy);
    5. Cardiac function: Echocardiography (ECHO) shows left ventricular ejection fraction (LVEF) > 50%.
  • Serum pregnancy test (for female of childbearing potential) negative within 3 days prior to first dosing of study treatment. Male and female patients of childbearing potential must agree to use effective methods of contraception from the time of first negative pregnancy test at screening, throughout the study and for 6 months after the last dose of the investigational product. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

Exclusion Criteria:

  • Has received any investigational agents within 21 days prior to the first administration of TSN084; or have stopped any investigational agents or other anti-tumors drugs for less than 5 half-lives or 21 days, whichever is longer;
  • Acute toxic effects of prior anti-tumor therapy have not recovered to clinically significant NCI-CTCAE V5.0 grade ≤1 toxicity or baseline prior to the first administration of TSN084.
  • At rest, the average Corrected QT interval (QTc, Fridericia's correction formula used) obtained by 12-lead Electrocardiograph (ECG) examination is > 470 ms (repeated 3 times). A variety of clinically significant arrhythmia, conduction, and resting ECG abnormalities, such as complete left bundle branch block, degree III, degree II, PR interval >250 ms. Various factors that may increase the risk of prolonged QTc or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome in a direct family member or sudden unexplained death before age 40, and use of any medications known to prolong QT intervals.
  • Has an acute or chronic active hepatitis B defined as hepatitis B virus (HBV) DNA copy number ≥1×103 copies/mL or ≥ 200 IU/ml.
  • Has acute or chronic active hepatitis C (HCV) defined as HCV-RNA level greater than the upper limit of the central reference value.
  • Patients with active brain metastases will be allowed to enroll if their central nervous system (CNS) tumor metastases are confined to the supratentorial or cerebellum, have been adequately treated (surgery or radiotherapy), have maintained radiographic stability for at least 4 weeks, and do not require corticosteroids to control symptoms.
  • Concurrent diseases that have not been controlled, such as:

    1. Severe infection, including but not limited to hospitalization due to infection, bacteremia, or severe pneumonia complications, occurs within 4 weeks prior to initiation of study treatment; Or patients who received therapeutic oral or intravenous antibiotics within two weeks prior to starting study treatment, and who received prophylactic antibiotics (e.g., for the prevention of urinary tract infection or chronic obstructive pulmonary disease);
    2. Symptomatic congestive heart failure (New York Heart Association Grades II-IV) or symptomatic or poorly controlled arrhythmias;
    3. Other malignancies (other than non-melanoma basal cell carcinoma or squamous cell carcinoma of the skin, breast/cervical carcinoma in situ, superficial bladder carcinoma that have received radical treatment and no evidence of disease recurrence) within 5 years prior to initiation of TSN084 treatment;
    4. Suspicion or confirmation of acute promyelocytic leukemia (for patients with acute myeloid leukemia) based on morphology, immune typing, molecular detection, or chromosome karyotype;
    5. Current subjects with cancerous meningitis, spinal cord compression, etc.;
    6. A history of poorly controlled hypertension;
    7. Symptomatic endogenous pulmonary disease;
    8. Any arterial thromboembolic event, including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, occurred within 6 months prior to enrolment;
    9. Significant malnutrition, such as the need for intravenous nutrient supplementation. Those who were stable for more than 4 weeks after correction of malnutrition before treatment of first dose of investigational product could be included.
    10. Tumor invasion of surrounding important organs or blood vessels (such as mediastinal great vessels, superior vena cava, trachea, esophagus, etc.), or at risk of esophagotracheal fistula or esophagopleural fistula;
    11. After endoesophageal or tracheal stent implantation;
    12. Other acute or chronic diseases or laboratory test abnormalities that may increase the risks associated with study participation or investigational product administration, or interfere with the interpretation of study results and, in the investigator's judgment, make subjects ineligible for study participation;
    13. Has a history of gastrointestinal perforation and/or fistula 6 months prior to the study enrollment;
    14. Uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients who do not need drainage effusion or have no significant increase in effusion after 3 days of cessation of drainage can be included).
  • Expected to receive other anti-tumor therapies during the study (palliative radiotherapy is allowed).
  • Allergic to TSN084 or its components.
  • Has active gastrointestinal disease or other disease, or other factors such as surgical resection that may significantly affect drug absorption, metabolism, or excretion. This includes but not limited to the following conditions: malabsorption syndrome, inflammatory bowel disease, partial or complete intestinal obstruction, gastric or small intestinal resection.
  • Has severe lung disease or history, such as moderate to severe chronic obstructive pulmonary disease (COPD), history of interstitial lung disease (ILD), drug-induced ILD, acute or chronic infectious pneumonia, lung transplantation, etc.
  • Use of strong inducers or inhibitors of CYP3A drugs.
  • Pregnant or lactating women.
  • Dysphagia.
  • Being involved in another interventional clinical study, or in an observational (non-interventional) clinical study, or in the follow-up phase of an interventional study.
  • Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Had a major surgical procedure (craniotomy, thoracotomy, laparotomy, vascular intervention, as defined by the investigator) within 4 weeks prior to the first administration of the investigational product, or had an unhealed wound, ulcer, or fracture. Note: For palliative care purposes, local surgical treatment of isolated lesions is acceptable.
  • HIV infected patients (HIV 1/2 antibody positive).
  • Known active syphilis infection, or active tuberculosis.
  • Has a clear history of mental disorder with ongoing treatment.
  • A history of drug abuse or drug use.
  • The investigator believes that the subject may have other factors that may affect the results of the study and interfere with the subject's participation in the entire study process, including previous or existing physical conditions, abnormal treatment or laboratory tests, and the subject's unwillingness to comply with all procedures, restrictions and requirements of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05300438

Layout table for location contacts
Contact: Han Fu +86-021-50720081

Layout table for location information
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Siqing Fu, MD, PhD         
Sponsors and Collaborators
Tyligand Bioscience (Shanghai) Limited
Layout table for investigator information
Principal Investigator: Siqing Fu, MD, PhD M.D. Anderson Cancer Center
Layout table for additonal information
Responsible Party: Tyligand Bioscience (Shanghai) Limited Identifier: NCT05300438    
Other Study ID Numbers: TSN084-101US
First Posted: March 29, 2022    Key Record Dates
Last Update Posted: April 25, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms